Cardiovascular Risk in Growth Hormone Deficient Young Adult Males After Completing Growth Hormone Therapy

NCT00711061 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 24

Last updated 2009-02-10

No results posted yet for this study

Summary

The purpose of this study is to compare the cardiovascular risks of growth hormone deficient young adult males who have completed growth hormone therapy to healthy young adult males.

Conditions

  • Growth Hormone Deficiency

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY
  • Children's Mercy Hospital Kansas City

    lead OTHER

Principal Investigators

  • Carol Huseman, MD · Children's Mercy Hospital Kansas City

Eligibility

Min Age
18 Years
Max Age
25 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-06-30
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00711061 on ClinicalTrials.gov